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Abstract
Background: Ectopic pregnancy (EP) remains the most life-threatening acute condition in modern gynaecology. It remains
difficult to diagnose early and accurately. Women often present at emergency departments in early pregnancy with a
‘pregnancy of unknown location’ (PUL) and diagnosis/exclusion of EP is challenging due to a lack of reliable biomarkers.
Recent studies suggest that serum levels of a disintegrin and metalloprotease protein-12 (ADAM-12) can be used
differentiate EP from viable intrauterine pregnancy (VIUP). Here we describe a prospective study evaluating the
performance of ADAM-12 in differentiating EP from the full spectrum of alternative PUL outcomes in an independent
patient cohort.
Methodology/Principal Findings: Sera were collected from 120 patients at their first clinical presentation with a PUL and
assayed for ADAM-12 by ELISA. Patients were categorized according to final pregnancy outcomes. Serum ADAM-12
concentrations were increased in women with histologically-confirmed EP (median 442 pg/mL; 25%–75% percentile 232–
783 pg/mL) compared to women with VIUP (256 pg/mL; 168–442 pg/mL) or miscarriage (192 pg/mL; 133–476 pg/mL).
Serum ADAM-12 did not differentiate histologically-confirmed EP from spontaneously resolving PUL (srPUL) (416 pg/mL;
154–608 pg/mL). The diagnostic potential of ADAM-12 was only significant when ‘ambiguous’ PUL outcomes were
excluded from the analysis (AROC= 0.6633; P = 0.03901).
Conclusions/Significance: When measured in isolation, ADAM-12 levels had limited value as a diagnostic biomarker for EP
in our patient cohort. The development of a reliable serum biomarker-based test for EP remains an ongoing challenge.
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Introduction
The diagnosis of ectopic pregnancy (EP) continues to present a
major clinical challenge in obstetrics and gynecology, with patients
often asymptomatic or presenting with non-specific symptoms that
do not readily differentiate EP from miscarriage or viable
intrauterine pregnancy.
Whilst in many cases, an EP will be detected by transvaginal
ultrasonography (TVUSS) at the first clinic visit [1], TVUSS is
often inconclusive and the pregnancy has to be initially classified as
a ‘‘pregnancy of unknown location’’ (PUL) [2]. In patients with a
PUL, subsequent diagnosis of EP relies on the serial measurement
of serum human chorionic gonadotrophin (hCG) levels (and, in
some centers, progesterone), together with follow-up TVUSS [3–
5]. This approach significantly delays the diagnosis and manage-
ment of EP and is resource intense and expensive [6]. There
remains an unmet clinical need for a serum biomarker capable of
identifying EP at first clinical presentation [5,7].
Recently, Rausch et al [8] found a statistically significant
decrease in a disintegrin and metalloprotease protein-12 (ADAM-
12) in the sera of patients with EP (median 2.5 ng/mL), when
compared to women with viable intrauterine pregnancy (median
18.6 ng/mL). The authors demonstrated this difference in a large
cohort of 199 patients in the United States presenting with pain or
bleeding in the first trimester of pregnancy. There appeared to be
good discrimination between the groups as assessed by receiver
operating characteristics (Area under ROC curve= 0.82;
P,0.0001). They concluded that serum ADAM-12 was a
promising biomarker for the diagnosis of ectopic pregnancy in
women with symptoms in the first trimester.
However, there is debate as to the specificity of ADAM-12 with
regard to differentiating EP from outcomes other than VIUP [9]
due to the fact that other conditions, such as trisomy 21 can also
present with alteration of ADAM-12 [10,11]. Furthermore, the
promising findings reported by Rausch et al needed independent
verification. We therefore set out to validate Rausch et al’s
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findings, measuring ADAM-12 in a cohort of women prospectively
recruited in the United Kingdom with a PUL.
Results
A total of 120 Caucasian women (aged 18–45 years) with a PUL
were recruited to the study. Patients’ final pregnancy outcomes
were classified according to the recent PUL consensus statement
[12]. Final outcome definitions and details of the demographics of
each group are provided in Table 1. There was no evidence of
variation in age, weight or BMI between different final outcomes
of PUL (one-way ANOVA).
Serum ADAM-12 concentrations were elevated in patients
with final outcomes of ‘definite ectopic pregnancy’ (dEP; median
442 pg/mL; 25% percentile 232 pg/mL, 75% percentile
783 pg/mL) when compared to: ‘definite viable intrauterine
pregnancy’ (dVIUP; median 256 pg/mL; 25% percentile
168 pg/mL, 75% percentile 442 pg/mL); ‘definite non-viable
intrauterine pregnancy’ (dNVIUP; median 192 pg/mL; 25%
percentile 133 pg/mL, 75% percentile 476 pg/mL); ‘probable
ectopic pregnancy’ (pEP; median 254 pg/mL; 25% percentile
152 pg/mL, 75% percentile 551 pg/mL); ‘treated probable PUL’
(tpPUL; median 177 pg/mL; 25% percentile 127 pg/mL, 75%
percentile 184 pg/mL); or ‘non-pregnant women’ (NP; median
283 pg/mL; 25% percentile 137 pg/mL, 75% percentile
442 pg/mL) (Figure 1A). Serum ADAM-12 levels in patients
with ‘spontaneously resolving PUL’ (srPUL; median 416 pg/mL;
25% percentile 154 pg/mL, 75% percentile 608 pg/mL) were
similar to those in patients with dEP (Figure 1A).
When patients with ‘ambiguous’ PUL outcomes (srPUL, pEP and
tpPUL) were included in the cohort for evaluation, ROC curve
analysis indicated that ADAM-12 had little value as a diagnostic
biomarker of EP (Area under ROC curve= 0.6465; P.0.05)
(Figure 1B). However, when only well defined PUL outcomes (dEP,
dVIUP, dNVIUP and NP) were included in the analysis, ADAM-12
appeared to have better diagnostic potential (Area under ROC
curve= 0.6633; P,0.05) for detecting dEP (Figure 1C).
Discussion
ADAM-12 may have some potential as a serum biomarker of
dEP. However, we were unable to verify the findings of Rausch et
al who had concluded ADAM-12 was a highly promising marker
of ectopic pregnancy with strong diagnostic marker performance.
In fact, we found that serum ADAM-12 concentrations in our UK
cohort were elevated in patients with dEP compared to dVIUP
(Figure 1A), rather than decreased as reported previously [8].
Furthermore, ADAM-12 did not appear to perform well as a
biomarker of ectopic pregnancy.
We can only speculate why we were unable to replicate the
promising findings described by Rausch et al [8]. They used a
dissociation-enhanced lanthanide fluoroimmunoassay platform
DELFIA/AutoDELFIA ADAM-12 research kit (PerkinElmer),
compared to the ADAM12 Quantikine ELISA (R&D systems)
used in the current study, and it is possible that the conflicting
findings are due to this difference. However, it seems unlikely that
this could account for the trend reversal observed between the two
cohorts and differences in study design offer a more plausible
explanation.
Gestational age is likely to be a key factor in ADAM12 levels, as
it rises exponentially from around week 5 of the first trimester [13].
Therefore, it seems possible that the lower levels of ADAM12 we
report reflect the gestational age of our prospectively collected first
presentation cohort. Our study population was also slightly smaller
Table 1. Patient recruitment: 120 patients with an initial diagnosis of a PUL were recruited to the study and grouped according to
final pregnancy outcomes.
Group Inclusion criteria HCG (mU/ml) Age (years) Weight (Kg) BMI n
dVIUP Definite viable intrauterine pregnancy: TVUSS
confirmation of intrauterine gestational sac with
yolk sac and embryo with cardiac activity.
684462017 2861 7064 2662 28
dNVIUP Definite nonviable intrauterine pregnancy: USS
confirmation of intrauterine gestational sac with
yolk sac and/or embryo without cardiac activity
seen prior to uterine evacuation.
402261904 3261 7463 2761 26
dEP Definite ectopic pregnancy: intervention prompted
by adnexal mass on TVUSS or by abnormal rise in
serum hCG levels and confirmed at surgery and
by histopathology.
11516238 2961 7064 2561 17
NP Not pregnant: positive home pregnancy test
result subsequently not confirmed by serum
hCG measurement.
,5 2662 7068 2763 11
srPUL Spontaneously resolving PUL: PUL with
spontaneous resolution of serum
hCG levels.
4286114 3261 7464 2861 27
tPUL Treated persistent PUL: abnormal rise in serum
hCG levels but no adnexal mass or IU sac seen on
TVUSS after monitoring, managed medically with
methotrexate.
4006188 3264 83615 2865 3
pEP Probable ectopic pregnancy: inhomogenous
adnexal mass or extrauterine sac-like structure
on TVUSS managed medically with methotrexate.
5976200 3361 6364 2561 8
doi:10.1371/journal.pone.0041442.t001
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(120 versus 199 participants) than that of Rausch et al. and we
only recruited from a single UK center whereas Rausch et al.
recruited from multiple US sites. This could potentially explain the
disparity in our findings.
Another key difference in the design of our study and that
published by Rausch et al. [8], is the inclusion of the entire range
of PUL outcomes in the study design, not just dEP and dVIUP.
Crucially, we found that serum ADAM-12 concentrations in
patients who required surgical intervention for dEP were very
similar to those observed in patients with final outcome of
srPUL, who did not require surgical or medical intervention
(Figure 1A).
Regardless of these differences, the discrepancy in the findings
of our study and those of Rausch et al. [8] demonstrates the
importance of verifying potential EP biomarkers in independent
cohorts, and preferably from multiple international centers. The
development of non-invasive blood biomarker test that reliably
diagnoses EP remains an ongoing challenge.
Materials and Methods
Patient samples
Ethical approval for this prospective study was obtained from
the Lothian Research Ethics Committee (LREC 04/S1103/20
and 09/S1103/39), with informed written consent obtained from
all patients. Whole blood was obtained from women during their
first clinical presentation with a positive home pregnancy test and
abdominal pain and/or bleeding and a TVS that had been unable
to locate the site of the pregnancy. After clotting for 2 hrs at RT,
sera were collected and stored at 280uC in multiple aliquots. The
women were monitored until their discharge from hospital and
their final pregnancy outcomes were classified according to the
recent PUL consensus statement [12].
Ultrasound assessments
The ultrasound system used was the Toshiba Aplio XG and all
of the ultrasound assessments were performed by a team of
trained, qualified and experienced ultrasonographers.
ADAM-12 ELISA
Sera were assayed using the ADAM12 Quantikine ELISA kit
(R&D systems, Abingdon, UK) according to the manufacturers’
instructions. Comprehensive details of the assay’s performance
parameters are available from the manufacturer (http://www.
rndsystems.com/pdf/DAD120.pdf).
Statistical Analysis
Statistical analyses, ELISA standard curve formulae and
receiver operating characteristic (ROC) curves were generated
using Prism 5.0 (GraphPad Software, La Jolla, USA).
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Figure 1. ADAM12 levels in sera collected from women at first
presentation with a PUL, categorised according to final
pregnancy outcome. Definite ectopic pregnancy (dEP: n = 17),
probable ectopic pregnancy (pEP: n = 8), definite viable intrauterine
pregnancy (dVIUP: n = 28), definite nonviable intrauterine pregnancy
(dNVIUP: n = 26), spontaneously resolving PUL (srPUL: n = 27), treated
persistent PUL (tpPUL: n = 3) and not pregnant (NP: n = 11). A ROC curve
was generated (‘ROC of ADAM12’) to compare serum ADAM12
concentrations in patients with a dEP versus all other outcomes. The
analysis was repeated (‘ROC of ADAM12 -PUL Data’) after ‘ambiguous’
pregnancy outcomes (srPUL, tpPUL and pEP) were excluded.
doi:10.1371/journal.pone.0041442.g001
ADAM-12 as a Biomarker of Ectopic Pregnancy
PLOS ONE | www.plosone.org 3 August 2012 | Volume 7 | Issue 8 | e41442
References
1. Kirk E, Papageorghiou AT, Condous G, Tan L, Bora S, et al. (2007) The
diagnostic effectiveness of an initial transvaginal scan in detecting ectopic
pregnancy. Hum Reprod: 22:2824–2828.
2. Condous G, Okaro E, Khalid A, Timmerman D, Lu C, et al. (2004) The use of a
new logistic regression model for predicting the outcome of pregnancies of
unknown location. Hum Reprod: 19:1900–1910.
3. Jurkovic D, Wilkinson H (2011) Diagnosis and management of ectopic
pregnancy. BMJ: 342:d3397.
4. Sivalingam VN, Duncan WC, Kirk E, Shephard LA, Horne AW (2011)
Diagnosis and management of ectopic pregnancy. J Fam Plann Reprod Health
Care: 37:231–240.
5. Barnhart K, Speicher DW (2011) Molecular diagnosis of ectopic pregnancy.
Expert Rev Mol Diagn: 11:759–762.
6. Wedderburn CJ, Warner P, Graham B, Duncan WC, Critchley HO, et al.
(2010) Economic evaluation of diagnosing and excluding ectopic pregnancy.
Hum Reprod: 25:328–333.
7. Horne AW, Duncan WC, Critchley HO (2010) The need for serum biomarker
development for diagnosing and excluding tubal ectopic pregnancy. Acta Obstet
Gynecol Scand: 89:299–301.
8. Rausch ME, Beer L, Sammel MD, Takacs P, Chung K, et al. (2011) A
disintegrin and metalloprotease protein-12 as a novel marker for the diagnosis of
ectopic pregnancy. Fertil Steril: 95:1373–1378.
9. Wiwanitkit V (2011) Disintegrin and metalloprotease and ectopic pregnancy.
Fertil Steril 95:e21; author reply e22.
10. Laigaard J, Spencer K, Christiansen M, Cowans NJ, Larsen SO, et al. (2006)
ADAM 12 as a first-trimester maternal serum marker in screening for Down
syndrome. Prenat Diagn: 26:973–979.
11. Tørring N, Ball S, Wright D, Sarkissian G, Guitton M, et al. (2010) First
trimester screening for trisomy 21 in gestational week 8–10 by ADAM12-S as a
maternal serum marker. Reprod Biol Endocrinol 29;8:129.
12. Barnhart K, van Mello NM, Bourne T, Kirk E, Van Calster B, et al. (2011)
Pregnancy of unknown location: a consensus statement of nomenclature,
definitions, and outcome. Fertil Steril: 95:857–866.
13. Sahraravand M, Ja¨rvela¨ IY, Laitinen P, Tekay AH, Ryyna¨nen M (2011) The
secretion of PAPP-A, ADAM12, and PP13 correlates with the size of the
placenta for the first month of pregnancy. Placenta : 32:999–1003.
ADAM-12 as a Biomarker of Ectopic Pregnancy
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e41442
